Figure S1 from The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia
posted on 2023-03-31, 18:26authored byAlba Matas-Céspedes, Anna Vidal-Crespo, Vanina Rodriguez, Neus Villamor, Julio Delgado, Eva Giné, Heleia Roca-Ho, Pablo Menéndez, Elías Campo, Armando López-Guillermo, Dolors Colomer, Gaël Roué, Adrian Wiestner, Paul W.H.I. Parren, Parul Doshi, Jeroen Lammerts van Bueren, Patricia Pérez-Galán
Figure S1. Effect of CRPs blockade on daratumumab-induced CDC. Daudi and CLL cells were labeled with Calcein-AM (1μM) and challenged to CDC induction by daratumumab (DARA), rituximab (RITUX), ofatumumab (OFA) or isotype control, all of them at 10μg/mL, in the presence of 10% Normal Human Serum (NHS).
Funding
Genmab and Janssen pharmaceuticals
Spanish Ministry of Economy and Competitivity
Instituto de Salud Carlos III
Spanish Ministry of Economy and Competitiveness & European Regional Development Fund (ERDF)